FDA Approves Subcutaneous Infliximab for IBD

The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn's disease.

Related Keywords

New York ,United States ,California ,Los Angeles ,Jean Frederic Colombel ,Andres Yarur ,Icahn School Of Medicine At Mount Sinai ,Drug Administration ,Celltrion United States ,Medical Center ,Icahn School ,Mount Sinai ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Crohns Disease ,Ulcerative Colitis ,Colitis ,Intravenous Iv ,Intravenous ,Tv ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Upper Respiratory Infection ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Abdomen ,Anemia ,Arthralgia , ,